Skip to main content

Urinary biomarkers of oxidative status in a clinical model of oxidative assault.

Publication ,  Journal Article
Il'yasova, D; Spasojevic, I; Wang, F; Tolun, AA; Base, K; Young, SP; Marcom, PK; Marks, J; Mixon, G; DiGiulio, R; Millington, DS
Published in: Cancer Epidemiol Biomarkers Prev
June 2010

BACKGROUND: We used doxorubicin-based chemotherapy as a clinical model of oxidative assault in humans. METHODS: The study recruited newly diagnosed breast cancer patients (n = 23). Urine samples were collected immediately before (T0) and at 1 hour (T1) and 24 hours (T24) after i.v. administration of treatment. Measurements included allantoin and the isoprostanes iPF(2alpha)-III, iPF(2alpha)-VI, and 8,12-iso-iPF(2alpha)-VI along with the prostaglandin 2,3-dinor-iPF(2alpha)-III, a metabolite of iPF(2alpha)-III. All biomarkers were quantified using liquid chromatography-tandem mass spectrometry. RESULTS: In all subjects, the levels of the biomarkers increased at T1: allantoin by 22% (P = 0.06), iPF(2alpha)-III by 62% (P < 0.05), iPF(2alpha)-VI by 41% (P < 0.05), 8,12-iso-iPF(2alpha)-VI by 58% (P < 0.05), and 2,3-dinor-iPF(2alpha)-III by 52% (P < 0.05). At T24, the F2-isoprostanes returned to their baseline levels; the levels of allantoin continued to increase, although the T24-T0 difference was not statistically significant. CONCLUSIONS: These results indicate that urinary F2-isoprostanes are valid biomarkers and allantoin is a promising biomarker of oxidative status in humans. IMPACT: The levels of biomarkers change quickly in response to oxidative assault and can be used to monitor oxidative status in humans in response to treatments related either to generation of free radicals (chemotherapy and radiation therapy) or to antioxidants (inborn metabolic diseases and Down syndrome).

Duke Scholars

Published In

Cancer Epidemiol Biomarkers Prev

DOI

EISSN

1538-7755

Publication Date

June 2010

Volume

19

Issue

6

Start / End Page

1506 / 1510

Location

United States

Related Subject Headings

  • Young Adult
  • Oxidative Stress
  • Middle Aged
  • Mass Spectrometry
  • Humans
  • Free Radicals
  • Female
  • F2-Isoprostanes
  • Epidemiology
  • Doxorubicin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Il’yasova, D., Spasojevic, I., Wang, F., Tolun, A. A., Base, K., Young, S. P., … Millington, D. S. (2010). Urinary biomarkers of oxidative status in a clinical model of oxidative assault. Cancer Epidemiol Biomarkers Prev, 19(6), 1506–1510. https://doi.org/10.1158/1055-9965.EPI-10-0211
Il’yasova, Dora, Ivan Spasojevic, Frances Wang, Adviye A. Tolun, Karel Base, Sarah P. Young, P Kelly Marcom, et al. “Urinary biomarkers of oxidative status in a clinical model of oxidative assault.Cancer Epidemiol Biomarkers Prev 19, no. 6 (June 2010): 1506–10. https://doi.org/10.1158/1055-9965.EPI-10-0211.
Il’yasova D, Spasojevic I, Wang F, Tolun AA, Base K, Young SP, et al. Urinary biomarkers of oxidative status in a clinical model of oxidative assault. Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1506–10.
Il’yasova, Dora, et al. “Urinary biomarkers of oxidative status in a clinical model of oxidative assault.Cancer Epidemiol Biomarkers Prev, vol. 19, no. 6, June 2010, pp. 1506–10. Pubmed, doi:10.1158/1055-9965.EPI-10-0211.
Il’yasova D, Spasojevic I, Wang F, Tolun AA, Base K, Young SP, Marcom PK, Marks J, Mixon G, DiGiulio R, Millington DS. Urinary biomarkers of oxidative status in a clinical model of oxidative assault. Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1506–1510.

Published In

Cancer Epidemiol Biomarkers Prev

DOI

EISSN

1538-7755

Publication Date

June 2010

Volume

19

Issue

6

Start / End Page

1506 / 1510

Location

United States

Related Subject Headings

  • Young Adult
  • Oxidative Stress
  • Middle Aged
  • Mass Spectrometry
  • Humans
  • Free Radicals
  • Female
  • F2-Isoprostanes
  • Epidemiology
  • Doxorubicin